

**MITHRA PHARMACEUTICALS SA/NV ANNOUNCES A POSITIVE EVOLUTION OF THE  
ON-GOING PHARMACODYNAMICS STUDIES FOR ITS THREE-MONTH IMPLANT  
ZORELINE®**

**Liège, Belgium 17 July 2015** – Mithra Pharmaceuticals SA/NV announces that the on-going pharmacodynamics studies for its three-month implant Zoreline® are proceeding well. Currently, 57 patients on a population of 140 needed have been recruited in the study. The first four patients have completed the study without any safety issue.

Zoreline® is the generic candidate of Zoladex®. It is a one-month implant that contains 3.6 mg of Goserelin and a three months implant that contains 10.8 mg of Goserelin developed by Novalon, a 50% subsidiary of Mithra.

The pharmacodynamics for the three-month implant started in Q1 2015. The pharmacodynamics and pharmacokinetics studies for the one-month implant are expected to commence in H2 2015. Results for pharmacodynamics and pharmacokinetics studies for both implants are expected in H2 2016, with interim results for the three months implant. These interim results should be available in the first week of Augustus.

The pharmacodynamics studies are designed to demonstrate the ability of Zoreline® 3.6 mg and 10.8 mg to respectively induce estradiol levels suppression to menopause level in women patients and serum testosterone levels suppression to castrate level in male patients with prostate cancer. The pharmacokinetics studies are designed to demonstrate the safety of Zoreline® 3.6 mg and 10.8 mg.

**For more information, please contact:**

**Julie Dessart**

Head of Communications  
+32 4 349 28 22  
+32 475 86 41 75  
[jdessart@mithra.com](mailto:jdessart@mithra.com)

**Jean-Manuel Fontaine**

Public Relations  
+32 4 349 28 22  
+32 476 96 54 59  
[jmfontaine@mithra.com](mailto:jmfontaine@mithra.com)

**François Fornieri, CEO/ Steven Peters, CFO**

+32 4 349 28 22  
[investorrelations@mithra.com](mailto:investorrelations@mithra.com)

## About Mithra

Mithra Pharmaceuticals SA, founded in 1999 as a spin-off of the University of Liège by Mr. François Fornieri and Prof. dr. Jean-Michel Foidart, is a pharmaceutical company focused on women's health. Mithra's mission is to support and assist women at every stage of their life, thereby improving their overall quality of life. As such the Company aims to become a worldwide leader in women's health by developing, manufacturing and commercialising proprietary, innovative and differentiated drugs and generic products in four therapeutic fields of women's health, fertility and contraception, menopause and osteoporosis, vaginal infections and cancers.

Mithra has a total headcount of approximately 85 staff members and is headquartered in Liège, Belgium. Further information can be found at: [www.mithra.com](http://www.mithra.com)

## Important information

*The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.*